On Dec. 2, 2025, the U.S. Food and Drug Administration (FDA), in coordination with the U.S. Department of Justice (DOJ), announced that the U.S. Marshals Service seized approximately 73,000 units of 7-hydroxymitragynine (7-OH) products—valued at roughly $1 million—from three firms in Missouri.

The seizure focused on foods and dietary supplement products, including liquid shots and tablets, containing concentrated 7-OH as an added ingredient. Concentrated 7-OH is increasingly recognized as having the potential for abuse because of its ability to bind to opioid receptors. It cannot be lawfully added to dietary supplements or conventional foods. These products are considered adulterated because 7-OH does not meet applicable safety standards. Also, the FDA has not approved 7-OH for medical use.

“This enforcement action is a strong step to protect Americans from the dangers of concentrated 7-OH products, which are potent opioids,” said FDA Commissioner Marty Makary, M.D., M.P.H. “We must be proactive and vigilant to address emerging threats to our communities and our kids.”

These recent operations demonstrate coordinated federal enforcement efforts against concentrated 7-OH products. The FDA reminds all manufacturers and distributors that they must ensure their products comply with all applicable federal requirements.